Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 40M | 11% |
| Gross Profit | 10M | 68.5% |
| Cost of Revenue | 30M | 0.4% |
| Operating expense | 74M | 59.2% |
| Net Income | -61M | 65% |
| EBITDA | -57M | 66.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 1.45B | 3.9% |
| Total Liabilities | 997M | 2% |
| Total Equity | 453M | 8% |
| Shares Outstanding | 274M | 0.5% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -45M | 16.2% |
| Cash from investing | 23M | 70% |
| Cash from financing | 810,000 | 634.2% |
EPS
Financial Highlights for Pacific Biosciences of California in Q3 '24
Pacific Biosciences of California reported a revenue of 40M, which is a 11% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 10M, marking a 68.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 30M, a -0.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 74M, showing a -59.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -61M, showing a 65% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -57M, showing a 66.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Pacific Biosciences of California with growth in revenue, gross profit, and net income.
